Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal Women
A Decentralized, Site-Anchored Hybrid, Open-Label, Single-Arm Proof-of-Concept Study Evaluating the Effect of Haelan 951 - a Fermented Soy Conventional Food Product - on Self-Reported Menopausal Vasomotor and Sleep-Related Outcomes in Post- and Peri-Menopausal Women
Spectrum Clinical Research, LLC
25 participants
Sep 21, 2026
INTERVENTIONAL
Conditions
Summary
This proof-of-concept, open-label, single-arm study is designed to evaluate the effects of daily consumption of Haelan 951, a fermented soy conventional food product, on self-reported menopausal vasomotor symptoms, sleep quality, and health-related quality of life in peri- and postmenopausal women. The study will collect descriptive data on participant-reported outcomes over the study period to assess the feasibility and potential effects of Haelan 951 in supporting menopausal wellness. The study is not intended to evaluate the treatment, prevention, or cure of any disease.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Haelan 951 is a fermented soy product administered orally once daily for 30 days. Participants will consume the study product according to the protocol to evaluate its effects on self-reported menopausal vasomotor symptoms, sleep quality, and health-related quality of life in peri- and postmenopausal women.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07751029